ClinicalTrials.gg
Active, not recruitingNCT07828197Updated Oct 1, 2026

A Pharmacokinetic Study of HDM1005 Injection at Different Injection Sites

A Phase 1 interventional study of HDM1005 in Overweight and/or Obesity and Healthy Participants, sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Updated Oct 1, 2026Interventions changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Obesity by Huadong Medicine Co., Ltd. — 10 open to participants now, 11 under way, 5 of them phase 3. Obesity · Huadong Medicine Co., Ltd..

Planned enrollment
9th of 13
135 · median 200
Started
2026
with 5 others
Phase 1
5 of 13
2 open now
Primary completion
2026-10
later than 6 of 10 live
Registered
13th of 13
by date

Among the 13 studies in Obesity by Huadong Medicine Co., Ltd., this one is the 9th largest by planned enrollment, is one of 6 that started in 2026, is one of 5 in phase 1, reaches primary completion later than 6 of the 10 other live ones, and was the 13th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

10 of the 13 studies in Obesity by Huadong Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Obesity by Huadong Medicine Co., Ltd., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the relative bioavailability of a single subcutaneous injection of HDM1005 solution at different injection sites (upper arm and thigh)by using the abdomen subcutaneous injection as a control.

03

Conditions studied

  • Overweight and/or Obesity
  • Healthy Participants
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 55 years (inclusive), regardless of gender.
  • Body weight ≥50.0 kg for males and ≥45.0 kg for females; (BMI) between 19.0 and 35.0 kg/m² (inclusive).
  • In the investigator's opinion, the participants do not have any abnormal findings based on medical history, clinical laboratory tests, vital signs, 12-lead , and physical examination at screening.
  • Provide signed before any trial procedures; fully understand the trial content, procedures, and possible adverse reactions.

Exclusion criteria

Exclusion Criteria:

  • Personal or family history of medullary thyroid carcinoma (MTC), thyroid C-cell hyperplasia, or multiple endocrine neoplasia type 2 (MEN2).
  • History of chronic pancreatitis, or an episode of acute pancreatitis within 3 months prior to screening.
  • History of acute cholecystitis within 3 months prior to screening.
  • Severe hypoglycemic events or recurrent hypoglycemic events (≥3 episodes per week) within 3 months prior to screening.
  • Presence of diseases involving any of the following systems at screening (including but not limited to respiratory, circulatory, digestive, hematopoietic, endocrine, immune, skin, nervous, psychiatric, ear-nose-throat, etc.), which in the investigator's opinion make the participant unsuitable.
  • History of specific allergy (such as asthma, urticaria, eczema, etc.) or allergic constitution; or known intolerance or allergy to any component of the drug or GLP-1 receptor (GLP-1R) agonists; or have a history of severe drug allergies.
  • Major surgery within 6 months prior to screening, or incomplete healing of surgical incisions, or planned surgery during the study.
  • Blood donation or blood loss ≥400 mL, or use of blood products within 3 months prior to screening or between screening and dosing.
  • History of drug abuse or positive urine drug test at screening.
  • Use of prescription or over-the-counter medications, health supplements, or herbal medicines within 2 weeks prior to IMP administration, or still within 5 half-lives of such medications.
  • Participation in any clinical trial and use of investigational product within 3 months prior to screening, or still within 5 half-lives of the investigational product from a previous trial at the time of screening (whichever is longer).
  • Female participants who are breastfeeding or pregnant.
  • History of needle phobia or hemophobia, difficulty with blood collection, or inability to tolerate venipuncture.
  • Any other condition (medical, psychological, psychiatric, social, or geographic factors) that, in the investigator's opinion, makes the participant unsuitable for the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
135 participants (estimated)

Study arms

  • Experimental
    Cohort 1 (Abdomen)

    Subject received a single subcutaneous injection of HDM1005 solution (0.5 mL, 2 mg) at abdomen.

    Drug: HDM1005

  • Experimental
    Cohort 2 (Upper arm)

    Subject received a single subcutaneous injection of HDM1005 solution (0.5 mL, 2 mg) at upper arm.

    Drug: HDM1005

  • Experimental
    Cohort 3 (Thigh)

    Subject received a single subcutaneous injection of HDM1005 solution (0.5 mL, 2 mg) at thigh.

    Drug: HDM1005

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum observed concentration

    Time frame: Up to Day 29

  2. AUC(0-t)

    Area under the curve from time 0 to t hour

    Time frame: Up to Day 29

  3. AUC(0-∞)

    Area under the curve from time 0 hour to ∞

    Time frame: Up to Day 29

Secondary outcomes

  1. Tmax

    Time to maximum plasma concentration

    Time frame: Up to Day 29

  2. t1/2

    Half life

    Time frame: Up to Day 29

  3. CL/F

    Apparent Clearance

    Time frame: Up to Day 29

  4. Vz/F

    Apparent volume of distribution

    Time frame: Up to Day 29

  5. Adverse events (AEs)

    Number of subjects reporting AEs

    Time frame: Up to Day 29

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Oct 2026, 1 month after the start.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 1 month is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2026
First posted
Sep 18, 2026
StartActual
Sep 3, 2026
Primary completionEst.
Oct 2026
CompletionEst.
Nov 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Interventions
Arm changed Cohort 1→Cohort 1 (Abdomen); Cohort 2→Cohort 2 (Upper arm); Cohort 3→Cohort 3 (Thigh)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Interventions Arm changed Cohort 1→Cohort 1 (Abdomen); Cohort 2→Cohort 2 (Upper arm); Cohort 3→Cohort 3 (Thigh)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07828197
Responsible party
Sponsor
First posted
Sep 18, 2026
Start date
Sep 3, 2026
Primary completion
Oct 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Oct 1, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HDM1005

Start the discussion